Eli Lilly (LLY) shares surged 8.7% following a robust Q1 earnings report that exceeded analyst expectations. The pharmaceutical giant reported earnings of $8.55 per share on sales of $19.8 billion, significantly surpassing the forecast of $6.97 per share and $17.6 billion in sales. This impressive performance was largely driven by its GLP-1 diet drugs, with revenue soaring 56% year over year and profits up 170%. However, the company faced a 13% price decline due to increased competition in the GLP-1 market.

Importantly, Lilly is not solely reliant on its GLP-1 business anymore. The company is actively diversifying its portfolio, with substantial growth in its immunology, oncology, and neuroscience divisions, which collectively grew by 160% this quarter. This shift is supported by recent acquisitions in gene therapy, indicating a strategic pivot that could reshape its revenue streams in the future.

Market professionals should note that while GLP-1 remains a key driver, Lilly’s expanding focus on oncology and other therapeutic areas could enhance its growth trajectory and mitigate risks associated with market competition.

Source: fool.com